AI-designed drug rentosertib slowed 6 of 6 proteomic aging clocks in trial
EricTopol · x · 2026-09-07
Insilico Medicine reports that rentosertib, a drug candidate designed with generative AI to treat chronic lung disease, may also slow aging.
- Results published in Nature Biotechnology, covered by NYT's Cade Metz
- In a small trial, the drug reduced proteomic aging clocks in 6 of 6 measures
- Researchers say the methods will be used in future trials; Eric Topol notes larger independent studies are needed
A milestone for AI drug discovery: one molecule targeting both a specific disease and the biology of aging.
Related event: AI-Designed IPF Drug Rentosertib Shows Biological Age Reversal in Trial(18 posts)→
More from Apps
- Resy's scorched-earth war on booking agents sets up a clash with big platforms — matt_slotnick · 2026-10-27
- Grok Impressions: Delegating Forms, Shopping and Payments to Grok Bot — XFreeze · 2026-10-27
- Analyst Ben Bajarin spends a weekend with iPhone Duo: 'most productive iPhone' — BenBajarin · 2026-10-27
- Vovy launches a cursor-following voice agent for Mac, free tier gives 100 credits/mo — Scobleizer · 2026-10-27
- FluidVoice launches premium on-device dictation, taking aim at WisprFlow and Willow — Scobleizer · 2026-10-27
- A heuristic for judging app value: look at how someone orders their iPhone share sheet — signulll · 2026-10-27